Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Corey

Showing results (81-90 of 222) with videos related to

Pageof 23
Sort By:
Science Advances|February 9, 2024
Stromal-derived MAOB promotes prostate cancer growth and progressionTianjie Pu, Jing Wang, Jing Wei, et al.
Research Square|April 8, 2024
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancerChengfei Liu, Bo Chen, Pengfei Xu, et al.
Nature Communications|December 11, 2025
BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interactionHee-Young Jeon, Sudeep Khadka, Majid Pornour, et al.
Frontiers in Endocrinology|April 17, 2023
ZBTB7A as a novel vulnerability in neuroendocrine prostate cancerSong Yi Bae, Hannah E Bergom, Abderrahman Day, et al.
Neoplasia (New York, N.Y.)|May 30, 2025
Alteration in expression and subcellular localization of the androgen receptor- regulated FAM111A protease is associated with emergence of castration resistant prostate cancerMaria Malvina Tsamouri, Stephen J Libertini, Salma Siddiqui, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancerNicole A Traphagen, Esmé Wheeler, Rong Li, et al.
Oncogene|June 14, 2024
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancerBo Chen, Pengfei Xu, Joy C Yang, et al.
American Journal of Translational Research|October 12, 2020
FOXA2 promotes prostate cancer growth in the boneZachary M Connelly, Renjie Jin, Jianghong Zhang, et al.
Molecular Cancer Therapeutics|February 15, 2020
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer ModelsUlrike Weyer-Czernilofsky, Marco H Hofmann, Katrin Friedbichler, et al.
Molecular Cancer Therapeutics|August 31, 2019
<i>COMMD3:BMI1</i> Fusion and COMMD3 Protein Regulate <i>C-MYC</i> Transcription: Novel Therapeutic Target for Metastatic Prostate CancerSyed Umbreen, Mudassir Meraj Banday, Anmbreen Jamroze, et al.
Pageof 23

Showing results (81-90 of 222) with videos related to

Sort By:
Pageof 23
Science Advances|February 9, 2024
Stromal-derived MAOB promotes prostate cancer growth and progressionTianjie Pu, Jing Wang, Jing Wei, et al.
Research Square|April 8, 2024
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancerChengfei Liu, Bo Chen, Pengfei Xu, et al.
Nature Communications|December 11, 2025
BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interactionHee-Young Jeon, Sudeep Khadka, Majid Pornour, et al.
Frontiers in Endocrinology|April 17, 2023
ZBTB7A as a novel vulnerability in neuroendocrine prostate cancerSong Yi Bae, Hannah E Bergom, Abderrahman Day, et al.
Neoplasia (New York, N.Y.)|May 30, 2025
Alteration in expression and subcellular localization of the androgen receptor- regulated FAM111A protease is associated with emergence of castration resistant prostate cancerMaria Malvina Tsamouri, Stephen J Libertini, Salma Siddiqui, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancerNicole A Traphagen, Esmé Wheeler, Rong Li, et al.
Oncogene|June 14, 2024
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancerBo Chen, Pengfei Xu, Joy C Yang, et al.
American Journal of Translational Research|October 12, 2020
FOXA2 promotes prostate cancer growth in the boneZachary M Connelly, Renjie Jin, Jianghong Zhang, et al.
Molecular Cancer Therapeutics|February 15, 2020
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer ModelsUlrike Weyer-Czernilofsky, Marco H Hofmann, Katrin Friedbichler, et al.
Molecular Cancer Therapeutics|August 31, 2019
<i>COMMD3:BMI1</i> Fusion and COMMD3 Protein Regulate <i>C-MYC</i> Transcription: Novel Therapeutic Target for Metastatic Prostate CancerSyed Umbreen, Mudassir Meraj Banday, Anmbreen Jamroze, et al.
Pageof 23